Neuren Pharmaceuticals Ltd(ASX: NEU)Bell Potter thinks that...

Neuren Pharmaceuticals Ltd(ASX: NEU)Bell Potter thinks that Neuren Pharmaceuticals could be one of the best ASX 200 shares to buy now.It is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options.Its first product, DAYBUE, is approved by the US Food and Drug Administration (FDA) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older.Whereas its second drug candidate, NNZ-2591, is in phase 2 development for multiple neurodevelopmental disorders. Positive results have been achieved in phase 2 clinical trials in Phelan-McDermid syndrome, Pitt Hopkins syndrome, and Angelman syndrome.Bell Potter is a big fan of the company. This is largely due to its NNZ-2591 drug candidate. It explains:NEU is a biotech company that is well-funded via its first asset, DAYBUE, which is an FDA approved trofinetide for the treatment of Rett syndrome. NEU's value is from its second asset, NNZ-2591, which is under development for rare diseases. NNZ-2591, if successful, could lead to a significant increase in revenue and earnings when brought to market. NEU looks attractive on a risk/adjusted basis after the recent sell-off.The broker has a buy rating and $25.00 price target on its shares. This implies potential upside of 76% for investors over the next 12 months.